drugset / Trial / NCT04137978

Study Evaluating Patients With Cystinuria

NCT04137978 ↗

Phase 2/3 Withdrawn Advicenne Pharma
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open label, multicentre study, evaluating the safety, tolerability, efficacy, compliance and acceptability of alkalising treatments at long-term in patients with cystinuria.

Timeline

Start
2024-05-01
Primary completion
2025-06
Completion
2025-08

Outcome

Outcome not reported

Stopped (Business): “Unspecified business decision/strategic reason”

Drugs

EvaluationDrugModalityDoseRoute
Comparator ADV7103 Unknown — —

Indications